Biofilms impact healing, reinfection
risk and antimicrobial effect

Biofilms can be present in 65% of skin infections and approximately 90% chronic infections

Biofilms pose a far-reaching threat to humans, animals and the environment. The continuing rise in antimicrobial resistance necessitates effective diagnosis and management of biofilm-associated infections. Collectively, infections contribute to significant morbidity, mortality and increased healthcare expenditures.

Biofilms delay healing, increase reinfection risk, contribute to antibiotic resistance.

Biofilms are powerful communities of bacteria that function as a single entity with defences that can produce chronic and recurrent infections. Bacteria are protected within a matrix, surrounded by a defensive “slime” layer, called the Extracellular Polymeric Substance (EPS) that adheres to surfaces and forms biofilms. The EPS acts as a physical barrier obstructing the penetration of antimicrobials, and host defences, making it difficult for treatments to reach the biofilm bacteria for eradication and removal. Pathogenic Biofilm Drives antimicrobial resistance.

BlastX® is a new innovation for the management of wounds. XBIO® technology takes an innovative approach to solving the problem of bacterial biofilms, combining broad spectrum efficacy and reducing the recurrent of infection.